ArriVent BioPharma (AVBP) Competitors $27.45 +0.86 (+3.23%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends AVBP vs. RYTM, IBRX, MLTX, PTCT, AGIO, XENE, VRNA, MRUS, VERA, and EWTXShould you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Rhythm Pharmaceuticals (RYTM), ImmunityBio (IBRX), MoonLake Immunotherapeutics (MLTX), PTC Therapeutics (PTCT), Agios Pharmaceuticals (AGIO), Xenon Pharmaceuticals (XENE), Verona Pharma (VRNA), Merus (MRUS), Vera Therapeutics (VERA), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry. ArriVent BioPharma vs. Rhythm Pharmaceuticals ImmunityBio MoonLake Immunotherapeutics PTC Therapeutics Agios Pharmaceuticals Xenon Pharmaceuticals Verona Pharma Merus Vera Therapeutics Edgewise Therapeutics ArriVent BioPharma (NASDAQ:AVBP) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation. Does the media refer more to AVBP or RYTM? In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than ArriVent BioPharma. MarketBeat recorded 10 mentions for Rhythm Pharmaceuticals and 5 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.61 beat Rhythm Pharmaceuticals' score of 0.49 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Rhythm Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, AVBP or RYTM? ArriVent BioPharma has higher earnings, but lower revenue than Rhythm Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33MN/AN/ARhythm Pharmaceuticals$112.53M32.74-$184.68M-$4.33-13.84 Do analysts prefer AVBP or RYTM? ArriVent BioPharma presently has a consensus target price of $36.80, indicating a potential upside of 34.06%. Rhythm Pharmaceuticals has a consensus target price of $62.30, indicating a potential upside of 3.94%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, research analysts clearly believe ArriVent BioPharma is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Rhythm Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Does the MarketBeat Community favor AVBP or RYTM? Rhythm Pharmaceuticals received 273 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 66.59% of users gave Rhythm Pharmaceuticals an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes16100.00% Underperform VotesNo VotesRhythm PharmaceuticalsOutperform Votes28966.59% Underperform Votes14533.41% Do insiders and institutionals believe in AVBP or RYTM? 9.5% of ArriVent BioPharma shares are owned by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is AVBP or RYTM more profitable? ArriVent BioPharma has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -230.07%. ArriVent BioPharma's return on equity of -43.89% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% Rhythm Pharmaceuticals -230.07%-367.36%-77.47% SummaryArriVent BioPharma beats Rhythm Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Ad Porter & CompanyFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVBP vs. The Competition Export to ExcelMetricArriVent BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$925.07M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E RatioN/A11.10105.1417.83Price / SalesN/A362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / Book3.3410.377.096.50Net Income-$69.33M$153.60M$119.65M$226.22M7 Day Performance0.88%4.60%2.25%4.03%1 Month Performance-9.23%-6.29%-2.33%4.92%1 Year PerformanceN/A33.41%33.98%29.30% ArriVent BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVBPArriVent BioPharma1.1193 of 5 stars$27.45+3.2%$36.80+34.1%N/A$925.07MN/A0.0040RYTMRhythm Pharmaceuticals3.1421 of 5 stars$59.94+1.5%$62.30+3.9%+78.8%$3.68B$112.53M-13.84140Analyst ForecastIBRXImmunityBio0.6284 of 5 stars$5.10+1.2%$4.75-6.9%+21.7%$3.55B$620,000.00-5.54590MLTXMoonLake Immunotherapeutics3.4771 of 5 stars$54.32+4.7%$79.00+45.4%+19.9%$3.47BN/A-42.112News CoveragePTCTPTC Therapeutics2.5891 of 5 stars$43.23+0.8%$42.00-2.8%+100.0%$3.33B$900.66M-7.281,410Analyst DowngradeAGIOAgios Pharmaceuticals3.3042 of 5 stars$55.68+0.3%$52.33-6.0%+153.6%$3.18B$26.82M4.90390XENEXenon Pharmaceuticals3.5584 of 5 stars$41.15+3.4%$57.45+39.6%+43.2%$3.14B$9.43M-14.59251Insider TradeVRNAVerona Pharma2.6481 of 5 stars$38.81+2.5%$43.83+12.9%+176.2%$3.12B$5.62M-20.2130Positive NewsMRUSMerus3.0095 of 5 stars$45.49+2.6%$85.45+87.9%+92.4%$3.11B$35.93M-11.3037Analyst ForecastVERAVera Therapeutics2.5961 of 5 stars$48.31+2.7%$59.22+22.6%+267.1%$3.06BN/A-18.5140Analyst ForecastEWTXEdgewise Therapeutics2.7014 of 5 stars$32.20+0.7%$39.50+22.7%+404.7%$3.05BN/A-21.4760Analyst ForecastNews CoverageGap Up Related Companies and Tools Related Companies Rhythm Pharmaceuticals Competitors ImmunityBio Competitors MoonLake Immunotherapeutics Competitors PTC Therapeutics Competitors Agios Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Verona Pharma Competitors Merus Competitors Vera Therapeutics Competitors Edgewise Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVBP) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVBP Stock Alerts